Janssen gains immunotherapies, boosts prostate portfolio with Aduro deal
This article was originally published in Scrip
Executive Summary
Johnson & Johnson's Janssen Biotech will pay up to $359m in upfront and milestone fees plus royalties to expand the companies' Zytiga-led prostate cancer portfolio with programs based on Aduro BioTech's immunotherapy technology.
You may also be interested in...
Immuno-Oncology Data Drive Deal Dollars Higher
Immuno-oncology deals command relatively high values, but transaction volumes are increasing annually at a steady pace, not skyrocketing despite intense interest in the field as big pharma companies remain selective IO dealmakers based on the strength of early-stage data.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.